Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products geared towards addressing unmet needs and providing unique and meaningful advantages to patients with renal disease and their healthcare providers. Patients have been and continue to be at the center of our 16-year corporate history.
Type
Public
HQ
New York, US
Size (employees)
193 (est)+5%
Keryx Biopharmaceuticals is headquartered in New York, US

Keryx Biopharmaceuticals Office Locations

Keryx Biopharmaceuticals has offices in New York, Boston
New York, US
Boston, US

Keryx Biopharmaceuticals Metrics

Keryx Biopharmaceuticals Summary

Market capitalization

$648.2 m

Closing share price

$6.3
Keryx Biopharmaceuticals's current market capitalization is $648.2 m.

Keryx Biopharmaceuticals Financials

Keryx Biopharmaceuticals's revenue is $32 m in FY, 2016 which is a 133.8% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$7 m$13.7 m$32 m

Revenue growth, %

133.8%

Gross profit

$9.2 m

Operating expense total

$54.1 m$122.1 m$124.7 m

EBIT

($47.1 m)($111.2 m)($111.1 m)

Net Income

($46.7 m)($111.5 m)($123.1 m)($161.1 m)

Operating cash flow

$41 m$18.6 m$126 m

Keryx Biopharmaceuticals Market Value History

Keryx Biopharmaceuticals Online Presence

Keryx Biopharmaceuticals Company Life

You may also be interested in